Related CAS #
106730-54-5 (free base); 119615-63-3 (HCl)
Synonym
Olprinone Free Base
IUPAC/Chemical Name
5-(imidazo[1,2-a]pyridin-6-yl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
InChi Key
JPAWFIIYTJQOKW-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19)
SMILES Code
CC1=C(c(cc2)cn3c2ncc3)C=C(C(N1)=O)C#N
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
250.26
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Xu X, Zhang G, Lu S. [Research status of olprinone in cardiovascular diseases]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018 Dec;30(12):1209-1212. Chinese. doi: 10.3760/cma.j.issn.2095-4352.2018.012.022. PMID: 30592961.
2: Han MX, Xu XW, Lu SQ, Zhang GX. Effect of olprinone on ischemia-reperfusion induced myocardial injury in rats. Biomed Pharmacother. 2019 Mar;111:1005-1012. doi: 10.1016/j.biopha.2019.01.010. Epub 2019 Jan 10. PMID: 30841413.
3: Mizushige K, Ueda T, Yukiiri K, Suzuki H. Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74. doi: 10.1111/j.1527-3466.2002.tb00085.x. PMID: 12397365.
4: Kertys M, Kosutova P, Mokra D, Mokry J. Development of rapid and high- throughput LC-MS/MS method for quantification of olprinone in rabbit plasma. Biomed Chromatogr. 2019 Oct;33(10):e4620. doi: 10.1002/bmc.4620. Epub 2019 Jul 15. PMID: 31215048.
5: Dobashi S, Watanabe I, Nakanishi R, Hisatake S, Kiuchi S, Kabuki T, Oka T, Fujii T, Ikeda T. Comparing the effects of milrinone and olprinone in patients with congestive heart failure. Heart Vessels. 2020 Jun;35(6):776-785. doi: 10.1007/s00380-019-01543-6. Epub 2019 Dec 21. PMID: 31865433.
6: Ueda T, Mizushige K. The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation. Curr Vasc Pharmacol. 2006 Jan;4(1):1-7. doi: 10.2174/157016106775203072. PMID: 16472171.
7: Retraction. Fukushima J Med Sci. 2017;63(2):126. doi: 10.5387/fms.63_126. PMID: 28794319; PMCID: PMC7049466.
8: Crisafulli C, Mazzon E, Galuppo M, Paterniti I, Caminiti R, Cuzzocrea S. Olprinone attenuates the development of ischemia/reperfusion injury of the gut. Intensive Care Med. 2010 Jul;36(7):1235-47. doi: 10.1007/s00134-010-1798-4. Epub 2010 Mar 27. PMID: 20349038.
9: Kosutova P, Mikolka P, Balentova S, Adamkov M, Calkovska A, Mokra D. Effects of PDE3 Inhibitor Olprinone on the Respiratory Parameters, Inflammation, and Apoptosis in an Experimental Model of Acute Respiratory Distress Syndrome. Int J Mol Sci. 2020 May 11;21(9):3382. doi: 10.3390/ijms21093382. PMID: 32403267; PMCID: PMC7247002.
10: Tsubokawa T, Ishizuka S, Fukumoto K, Ueno K, Yamamoto K. The effect of hemodilution by cardiopulmonary bypass on protein binding of olprinone. J Anesth. 2013 Jun;27(3):346-50. doi: 10.1007/s00540-012-1524-1. Epub 2012 Nov 23. PMID: 23179741.
